# SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST

Source: https://onco.cc/trials/nct07633873/  
OnCo record `nct07633873` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tislelizumab, paclitaxel / nab-paclitaxel, cisplatin and carboplatin in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.

## Summary

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） is a phase 3, randomised interventional study registered as NCT07633873 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 500 participants, started 2026-06-02 and due to reach its primary completion in 2027-09-30. Interventions recorded: SYS6010 injection; Enlonstobart injection; Tislelizumab injection; Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS) assessed by IRC. Lung eligibility wording from the registry: "Participants with pathologically confirmed locally advanced or metastatic NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07633873
- Phase: 3
- Setting: An Open-label, Multicenter Randomized Phase III Study of SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy as First-Line Treatment for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT07633873: https://clinicaltrials.gov/study/NCT07633873

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07633873.json